Michael Andriole

Chief Executive Officer presso CHIMERIX, INC.

Patrimonio netto: 398 296 $ in data 30/04/2024

51 anni

Health Technology

Consumer Services

Posizioni attive di Michael Andriole

Società	Posizione	Inizio	Fine
CHIMERIX, INC.	Director/Board Member	01/08/2023	-
	Chief Executive Officer	01/08/2023	-
	President	01/08/2023	-
	Director of Finance/CFO	31/05/2019	01/08/2023
	Corporate Officer/Principal	08/04/2019	31/05/2019

Società	Posizione	Inizio	Fine
ENDOCYTE, INC.	Director of Finance/CFO	21/02/2017	01/12/2018
ELI LILLY AND COMPANY	Corporate Officer/Principal	01/08/2006	01/02/2017

Kelley School of Business	Masters Business Admin
Williams College of Business	Undergraduate Degree

Distribuzione geografica

Stati Uniti

Posizioni

Director of Finance/CFO	2
Corporate Officer/Principal	2
Undergraduate Degree	1

Settori

Health Technology	4
Consumer Services	3

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Società quotate in Borsa	2
ELI LILLY AND COMPANY	Health Technology
CHIMERIX, INC.	Health Technology

Aziende private	1
Endocyte, Inc. Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN.	Health Technology

Aziende private

Health Technology